Model to predict the survival benefit of radiation for patients with rhabdomyosarcoma after surgery: A population-based study

Shen,Weidong; Sakamoto,Naoko; Yang,Limin

doi:10.3892/ijo.2014.2466

Model to predict the survival benefit of radiation for patients with rhabdomyosarcoma after surgery: A population-based study

Authors:
- Weidong Shen
- Naoko Sakamoto
- Limin Yang
View Affiliations

Affiliations: The Institute of Otolaryngology, Department of Otolaryngology, Head and Neck Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Public Health, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan, Epidemiology and Clinical Research Center for Children's Cancer, National Center for Child Health and Development, Tokyo 157-8535, Japan
Published online on: May 26, 2014 https://doi.org/10.3892/ijo.2014.2466
Pages: 549-557

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to build a model to predict the survival benefit of radiotherapy for resected rhabdomyosarcoma at the individual level, to help clinicians and their patients make more informed decisions about adjuvant radiotherapy. Patients with resection of rhabdomyosarcoma between 1990 and 2010 were derived from the Surveillance, Epidemiology and End Results database. A multivariate Cox proportional hazard model was built to model cause-specific survival. We used inverse-probability weighting with propensity scores to minimize selection bias in the observation study. The Akaike information criterion technique was used to reduce variables in the model. Nomograms were created with the reduced model after model selection. The study cohort comprised 1578 patients. The 5-year cause-specific survival rate was 64.3% (95% confidence interval (CI) 61.7?66.9%) and the 10-year cause-specific survival rate was 61.4% (95% CI, 58.7-64.2%) for the entire cohort. Five-year cause-specific survival rates were 62.3% (95% CI, 58.6-66.2%) and 66.1% (95% CI, 62.6-69.8%) for patients with surgery alone and adjuvant radiotherapy, respectively (P<0.01). Age, size, histological type, tumor stage, positive regional nodes and adjuvant radiotherapy were retained in the reduced model. Model performance was good, with a c-index of 0.78 (95% CI, 0.76-0.80). This clinical predictive tool can quantify the benefit of adjuvant radiotherapy after resection of rhabdomyosarcoma, and provide patients and clinicians with assistance in treatment selection.

View Figures

View References

1	No authors listed: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973–2010) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969–2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
2	Miller RW, Young JL Jr and Novakovic B: Childhood cancer. Cancer. 75:395–405. 1995. View Article : Google Scholar : PubMed/NCBI
3	Jha P, Frölich AM, McCarville B, et al: Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging. Pediatr Radiol. 40:1380–1386. 2010. View Article : Google Scholar : PubMed/NCBI
4	Raney RB, Maurer HM, Anderson JR, et al: The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 5:9–15. 2001. View Article : Google Scholar : PubMed/NCBI
5	Terezakis SA and Wharam MD: Radiotherapy for rhabdomyosarcoma: indications and outcome. Clin Oncol. 25:27–35. 2013. View Article : Google Scholar : PubMed/NCBI
6	Wolden SL, Anderson JR, Crist WM, et al: Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol. 17:3468–3475. 1999.PubMed/NCBI
7	Regine WF, Fontanesi J, Kumar P, et al: Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients. Int J Radiat Oncol Biol Phys. 31:485–491. 1995. View Article : Google Scholar : PubMed/NCBI
8	Schwartz CL: Long-term survivors of childhood cancer: the late effects of therapy. Oncologist. 4:45–54. 1999.PubMed/NCBI
9	Stevens MC: Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol. 6:77–84. 2005. View Article : Google Scholar : PubMed/NCBI
10	Schuck A, Mattke AC, Schmidt B, et al: Group II rhabdomyosarcoma and rhabdomyosarcoma-like tumors: is radiotherapy necessary? J Clin Oncol. 22:143–149. 2004. View Article : Google Scholar : PubMed/NCBI
11	Raney RB, Anderson JR, Barr FG, et al: Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 23:215–220. 2001. View Article : Google Scholar
12	Koscielniak E, Harms D, Henze G, et al: Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 17:3706–3719. 1999.PubMed/NCBI
13	Stevens MC, Rey A, Bouvet N, et al: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 23:2618–2628. 2005. View Article : Google Scholar : PubMed/NCBI
14	No authors listed: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
15	Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C and Ferrari A: Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 27:3391–3397. 2009. View Article : Google Scholar : PubMed/NCBI
16	Harrell FE: rms: Regression Modeling Strategies. R package version 3.6–3. http://CRAN.R-project.org/package=rms.
17	Austin PC: The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 29:661–677. 2009. View Article : Google Scholar
18	Austin PC, Grootendorst P and Anderson GM: A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 26:734–753. 2007. View Article : Google Scholar
19	Harrell FE: Regression Modeling Strategies. Springer-Verlag; New York, New York: 2001, View Article : Google Scholar
20	R Core Team. 2013, R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: URL http://www.R-project.org/.
21	Stephenson AJ, Scardino PT, Kattan MW, et al: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 25:2035–2041. 2007. View Article : Google Scholar : PubMed/NCBI
22	Rouzier R, Pusztai L, Delaloge S, et al: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 23:8331–8339. 2005. View Article : Google Scholar : PubMed/NCBI
23	Brennan MF, Kattan MW, Klimstra D and Conlon K: Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 240:293–298. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kattan MW, Karpeh MS, Mazumdar M and Brennan MF: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 21:3647–3650. 2003. View Article : Google Scholar : PubMed/NCBI
25	Yang L, Shen W and Sakamoto N: Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 31:468–474. 2013. View Article : Google Scholar : PubMed/NCBI
26	Kutikov A, Egleston BL, Wong YN and Uzzo RG: Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 28:311–317. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kattan MW, Leung DH and Brennan MF: Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 20:791–796. 2002.PubMed/NCBI
28	Gronchi A, Miceli R, Shurell E, et al: Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 31:1649–1655. 2013. View Article : Google Scholar
29	Chisholm JC, Marandet J, Rey A, et al: Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol. 29:1319–1325. 2011. View Article : Google Scholar
30	Wang SJ, Fuller CD, Kim JS, Sittig DF, Thomas CR Jr and Ravdin PM: Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol. 26:2112–2117. 2008. View Article : Google Scholar : PubMed/NCBI
31	Wang SJ, Lemieux A, Kalpathy-Cramer J, et al: Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 29:4627–4632. 2011. View Article : Google Scholar : PubMed/NCBI
32	Albert JM, Liu DD, Shen Y, et al: Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol. 30:2837–2843. 2012. View Article : Google Scholar : PubMed/NCBI
33	Flamant F, Rodary C, Rey A, et al: Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer. 34:1050–1062. 1998. View Article : Google Scholar : PubMed/NCBI
34	Austin PC: The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 32:2837–2849. 2013. View Article : Google Scholar : PubMed/NCBI